U.S. Markets closed

Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering.

RDI Initiates Coverage on:

Immune Design Corp.

Histogenics Corporation

Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded. The stock hit a new low of $1.47 on Friday after Wall Street learned that the company discontinued its CMB305 cancer vaccine program. Immune Design announced late Thursday it made the design after an early analysis of a phase 2 study showed CMB305 combined with Tecentriq is not likely to show a survival benefit in relapsed synovial sarcoma patients. Following the announcement, Leerink analyst Jonathan Chang slashed his rating on Immune Design to market perform from outperform and reduced his price target on the stock from $7 to $3. Chang wrote that, "in the context of past disappointments that have pressured IMDZ shares, we believe this recent update could add to investor concerns on company execution, which has been a critical part of the IMDZ story." Shares are down over 83% in the last 12 months.

Access RDI’s Immune Design Corp. Research Report at:

Histogenics Corporation shares saw a gain of a little over 12% on Friday on about 7.6 million shares traded. The company announced last week the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The net proceeds to Histogenics from this offering are approximately $15.4 million. The company is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Its lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.

Access RDI’s Histogenics Corporation Research Report at:

Our Actionable Research on Immune Design Corp. (NASDAQ: IMDZ) and Histogenics Corporation (NASDAQ: HSGX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:




CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com